May 19, 2023
The University of Cincinnati Cancer Center's Syed Ahmad, MD, is the national principal investigator for a phase 2 trial testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
June 30, 2023
A monthslong shortage of chemotherapies forces some patients to receive less treatment. University of Cincinnati Cancer Center's Davendra Sohal told the Wall Street Journal his patients were also impacted.
April 11, 2023
The University of Cincinnati's Atsuo Sasaki, PhD, is leading a multidisciplinary team that received National Institutes of Health funding to learn more about how an enzyme that was previously overlooked helps regulate lysosome and cellular function.
April 13, 2023
The University of Cincinnati is enrolling patients in an Imvax study that will test the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
April 14, 2023
University of Cincinnati Cancer Center researchers will present more than a dozen abstracts at the American Association for Cancer Research Annual Meeting 2023, held in Orlando, Florida, April 14-19, including findings that could advance treatments for head and neck and breast cancers.
April 21, 2023
Local 12 and WCPO highlighted the Imvax trial being hosted at the University of Cincinnati that is testing the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
December 8, 2022
Physics World recognized the University of Cincinnati's first-in-human trial of FLASH radiotherapy as one of the Top 10 Breakthroughs of the Year for 2022.
February 7, 2023
The National Cancer Institute (NCI) has announced an intent to fund research from the University of Cincinnati’s Andrew Waters, PhD, to better understand how to overcome treatment resistance and develop better treatments for KRAS-mutated pancreatic cancer.
February 8, 2023
Local 12 highlighted the University of Cincinnati's Andrew Waters and his research into novel treatments for pancreatic cancer.
September 7, 2022
University of Cincinnati researchers recently published study results in JAMA Otolaryngology showing that administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer did not increase rates of complication during and after surgery.